Prognostic prediction of lung adenocarcinoma by integrative analysis of RHOH expression and methylation

Clin Respir J. 2023 Mar;17(3):148-156. doi: 10.1111/crj.13574. Epub 2023 Jan 29.

Abstract

Background and objective: The development of epigenetics holds great promise for diagnosis and treatment of lung adenocarcinoma (LUAD). The purpose of this work was to analyze the correlation between Ras Homolog Gene Family Member H (RHOH) expression and methylation in patients with LUAD and its association with survival.

Methods: Data related to gene expression, DNA methylation, and clinical features of LUAD from The Cancer Genome Atlas (TCGA) database were analyzed. A total of 50 patients were included in verification group. The methylation level of RHOH in verification group was detected by bisulfite amplicon sequencing.

Results: The RHOH methylation level in TCGA cohort was significantly and negatively correlated with its expression level (Cor = -0.5, p = 2.687e-33). Patients with hypermethylation and low expression of RHOH had significantly worse prognosis than patients with hypomethylation and low expression of RHOH (TCGA: p = 0.004; validation cohort: p = 0.006, HR: 4.740, 95% CI: 1.567-14.340).

Conclusion: Our research revealed that RHOH may prove to be a new potential prognostic predictor for LUAD patients.

Keywords: RHOH; TCGA; lung adenocarcinoma; methylation; prognosis.

MeSH terms

  • Adenocarcinoma of Lung* / pathology
  • Biomarkers, Tumor / metabolism
  • DNA Methylation
  • Humans
  • Lung Neoplasms* / pathology
  • Prognosis

Substances

  • Biomarkers, Tumor
  • RhoH protein, human